City of Hope — Developing Bispecific Antibody Therapies to Improve Multiple Myeloma Treatment
By pinpointing genetic vulnerabilities in cancer cells and harnessing the power of the immune system to attack those cells, City of Hope is advancing novel immunotherapeutic modalities like bispecific antibody treatment to defeat multiple myeloma. Unlike standard antibody drugs, bispecific antibodies are uniquely engineered to bind to both cancer cells and T cells, engaging T cells to target and destroy cancer cells while minimizing side effects.